Recombinant Cynomolgus/Rhesus macaque B2M/beta 2-Microglobulin Protein
Beta LifeScience
SKU/CAT #: BLK-02710P-100UG

Cynomolgus/Rhesus macaque B2M on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Cynomolgus/Rhesus macaque B2M/beta 2-Microglobulin Protein
Beta LifeScience
SKU/CAT #: BLK-02710P-100UG
Collections: Fc receptors, Other recombinant proteins, Recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Cynomolgus/Rhesus macaque B2M/beta 2-Microglobulin Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Ile21-Met119. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
Accession | Q8SPW0 |
Target Symbol | B2M/beta 2-Microglobulin |
Synonyms | Beta-2-microglobulin;B2M |
Species | Cynomolgus/Rhesus macaque |
Expression System | HEK293 |
Tag | C-His |
Expression Range | Ile21-Met119 |
Mol. Weight | The protein has a predicted MW of 12.7 kDa. Due to glycosylation, the protein migrates to 13-15 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | The genetic and functional analysis of β2-microglobulin (B2M), a component of the HLA class-I complex.Acquired homozygous loss of B2M that caused lack of cell-surface HLA Class I expression in the tumor and a matched patient-derived xenograft (PDX). Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. |